Provided by Tiger Fintech (Singapore) Pte. Ltd.

Crinetics Pharmaceuticals Inc.

31.77
-0.4000-1.24%
Volume:557.24K
Turnover:17.62M
Market Cap:2.98B
PE:-8.32
High:32.13
Open:31.42
Low:31.18
Close:32.17
Loading ...

Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug

MT Newswires Live
·
28 Mar

Crinetics Pharmaceuticals Announces European Medicines Agency (Ema) Validation of Marketing Authorization Application (Maa) and Orphan Drug Designation (Odd) for Paltusotine in Acromegaly

THOMSON REUTERS
·
28 Mar

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

GlobeNewswire
·
28 Mar

U.S. RESEARCH ROUNDUP-Ashland, Connectone Bancorp, Neurocrine Biosciences

Reuters
·
26 Mar

BUZZ-Stifel initiates Crinetics Pharma with 'buy' on FDA approval prospects

Reuters
·
25 Mar

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target

MT Newswires Live
·
25 Mar

Crinetics Pharmaceuticals Initiated at Buy by Stifel

Dow Jones
·
25 Mar

BRIEF-Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
11 Mar

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
11 Mar

BUZZ-Morgan Stanley initiates Crinetics with 'outperform' on catalyst rich 2025

Reuters
·
08 Mar

Crinetics Pharmaceuticals Inc : Morgan Stanley Assumes Coverage With Overweight Rating; Price Target $70

THOMSON REUTERS
·
07 Mar

Promising Pipeline and Strategic Initiatives Drive Buy Rating for Crinetics Pharmaceuticals

TIPRANKS
·
07 Mar

Crinetics Pharmaceuticals Full Year 2024 Earnings: Revenues Disappoint

Simply Wall St.
·
01 Mar

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
01 Mar

Crinetics Pharmaceuticals Is Maintained at Market Outperform by Citizens Capital Markets

Dow Jones
·
28 Feb

Crinetics Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

TD Cowen Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

TIPRANKS
·
28 Feb

Crinetics Pharmaceuticals Q4 Net Loss Narrows

MT Newswires Live
·
28 Feb

Earnings Flash (CRNS) Crinetics Pharmaceuticals Q4 Loss Per Share $0.88 vs. FactSet Est Loss $0.89

MT Newswires Live
·
28 Feb

Crinetics Pharmaceuticals Q4 GAAP EPS $(0.88), Inline

Benzinga
·
28 Feb